CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 98 enrolled
Drug / intervention
sipuleucel-T +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01133704
NCT01133704Phase 3Completed
CompareCT.gov

A Randomized, Double Blind, Placebo Controlled Trial of Immunotherapy With Autologous Antigen-Loaded Dendritic Cells (Provenge®, APC8015) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer

Dendreon·interventional·Posted May 31, 2010·Updated Sep 8, 2010

In Brief

A Phase 3 clinical trial evaluating sipuleucel-T and APC-Placebo for Hormone-Refractory Prostate Cancer. Completed, enrolled 98 participants.

Detailed Summary

This is a randomized, double blind, placebo controlled trial of immunotherapy with autologous antigen-loaded dendritic cells (Provenge, APC8015) for asymptomatic, metastatic, hormone-refractory prostate cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHormone-Refractory Prostate Cancer
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 31, 2010
Enrollment StartMay 1, 2000
Primary CompletionMar 1, 2003
Study CompletionMay 1, 2005
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 16.1 years ago

Interventions

sipuleucel-Tbiological

APC-Placebobiological